

B1
than a heat shock protein, a complex of a heat shock protein and a peptide, RAP, alpha (2) macroglobulin, or a complex of alpha (2) macroglobulin and a peptide.

B2
71. (twice amended) A method for modulating an immune response comprising administering to a human a purified compound which binds to the alpha (2) macroglobulin receptor, in an amount effective to modulate the immune response of said human, wherein the compound is other than a heat shock protein, a complex of a heat shock protein and a peptide, RAP, alpha (2) macroglobulin, or a complex of alpha (2) macroglobulin and a peptide.

Add new claims 85-91 as follows:

85 (new) The method of claim 31 or 71 wherein the immune response is to an autoimmune antigen.

86 (new) The method of claim 31 or 71 wherein the immune response is to an infectious disease antigen.

87 (new) The method of claim 31 or 71 wherein the immune response is to an proliferative cell disorder other than cancer.

B3
88 (new) The method of claim 31 or 71 wherein the immune response is to a cancer antigen.

89 (new) The method of claim 88, wherein the cancer is selected from the group consisting of: human sarcomas or carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma,

embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendrogioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemias, polycythemia vera, lymphoma, multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease.

90 (new) The method of claim 86, wherein the infectious disease is caused by a infectious agent selected from the group consisting of: hepatitis type B virus, adeno-associated virus, cytomegalovirus, papilloma virus, polyoma viruses, SV40, adenoviruses, herpes simplex type I, herpes simplex type II, Epstein-Barr virus, poxviruses, variola vaccinia virus, RNA viruses, human immunodeficiency virus type I, human immunodeficiency virus type II, human T-cell lymphotropic virus type I, human T-cell lymphotropic virus type II, influenza virus, measles virus, rabies virus, Sendai virus, poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, rubella virus, Semliki forest virus, arboviruses, hepatitis type A virus, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Salmonella typhi*, *Treponema pallidum*, *Treponema pertenue*, *Treponema carateum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, *Helicobacter pylori*, *Entamoeba histolytica*, *Trichomonas tenas*, *Trichomonas hominis*, *Trichomonas vaginalis*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, *Trypanosoma cruzi*, *Leishmania donovani*, *Leishmania tropica*, *Leishmania braziliensis*, *Pneumocystis pneumonia*, *Plasmodium vivax*, *Plasmodium falciparum*, and *Plasmodium malaria*.

B3

91 (new) The method of claim 85, wherein the autoimmune disorder is selected from the group consisting of: insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura, rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility, Goodpasture's disease, bullous pemphigoid, discoid lupus, ulcerative colitis, and dense deposit disease.

REMARKS

Claims 31, 32, 71, and 75-84 were pending in this application. By this amendment claims 31 and 71 have been amended, and new claims 85-91 have been added, to clarify the invention.

The amendments and new claims are fully supported by the specification as originally filed, and, as such, no new matter has been added. In particular, support for the amendments can be found at the following portions of the specification: page 9, line 2; page 12, lines 13 to 20; and page 3, line 34 through page 4, line 15, and support for the new claims is found in Sections 5.7, 5.8, and 5.8 beginning at page 65, line 4, and ending at page 67, line 14.

A marked-up version of the claim amendments is attached hereto as Exhibit A, showing deleted matter by brackets and added matter by underlying. A copy of the claims as pending is attached hereto as Exhibit B.

Therefore, claims 31, 32, 71, and 75-91 will be pending upon entry of the present amendment. Applicants respectfully request that the amendments and remarks made herein be entered into the record of the instant application.

1. THE REJECTION UNDER 35 U.S.C. § 112, SECOND PARAGRAPH, SHOULD BE WITHDRAWN

Claims 31, 32, 71, and 75-84 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicants regard as the invention. Applicants respectfully assert that these rejections have been overcome and/or obviated, for the following reasons.